FGF-23 Antibody (283507) [Unconjugated]

FGF‑23 was detected in perfusion fixed frozen sections of mouse brain (cortex) using Rat Anti-Mouse FGF‑23 Monoclonal Antibody (Catalog # MAB26291) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Rat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS017) and counterstained with hematoxylin (blue). Specific staining was localized to glial cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

• Reactivity: Mu
• Applications: IHC
• Clone: 283507
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated
• Concentration: LYOPH

FGF-23 Antibody (283507) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse FGF-23
  Tyr25-Val251 (Arg179Gln)
  Accession # Q9EPC2
• Specificity: Detects mouse FGF-23 in direct ELISAs and Western blots. In direct ELISAs, this antibody shows approximately 50% cross-reactivity with recombinant human (rh) FGF-23. In Western blots, this antibody does not cross-react with rhFGF-3, -4, -5, -7, -9, -10, -11, -12, -13, -16, -17, -18, -19, acidic, basic, rmFGF-8b, -8c, -15, or -21.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Gene: Fgf23
• Purity: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 8-25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Purity: Protein A or G purified from hybridoma culture supernatant
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for FGF-23 Antibody (283507) [Unconjugated]

• ADHR
• FGF23
• FGF-23
• fibroblast growth factor 23
• HPDR2
• HYPF
• phosphatonin
• PHPTC
• tumor-derived hypophosphatemia inducing factor
• Tumor-derived hypophosphatemia-inducing factor

Background

Fibroblast growth factor 23 (FGF-23) is a 30-32 kDa member of the FGF gene family. Based on its structure, it is further classified as an FGF19 subfamily member. This subfamily includes FGF-19, -21, and -23. Like all other FGF subfamilies, FGF-19 subfamily members contain a 120 amino acid (aa) core FGF domain that exhibits a beta -trefoil structure (1, 2). Unlike other FGF subfamilies, FGF-19 subfamily members exist as highly diffusible molecules that is attributed to poor ECM/heparin sulfate binding (3-6). The cDNA for mouse FGF-23 predicts a 251 aa polypeptide that contains a 24 aa signal sequence and a 227 aa mature region (7). Mature mouse FGF-23 shows 72% aa identity to human FGF-23 (8). The FGF-19 subfamily shares an unusual receptor configuration. The standard model for FGF signaling requires an FGF:FGF R:heparin sulfate complex. Given FGF-23’s minimal association with heparin, a substitute termed ( alpha -) Klotho has evolved that serves the same function. Although FGF-23 binds to the widely expressed “c” isoforms of FGF R1 and 3 plus FGF R4, Klotho has a restricted distribution that limits FGF-23 activity (10-12). It should be noted that heparin-dependency has been reported for FGF-19 signaling, and this observation may extend to FGF-23 (13). The FGF-19 subfamily is considered endocrine in nature. All three subfamily members impact some aspect of metabolism and all three are induced by a nuclear receptor heterodimer that includes the retinoid X receptor (14-16). FGF-23 is considered a phosphatonin; that is, a molecule that reduces circulating plasma phosphate. It is produced by osteocytes and osteoblasts in response to high circulating phosphate levels, elevated parathyroid hormone that induces hypercalcemia, and circulatory volume loading. Upon binding to FGF-23 receptors on renal proximal tubular epithelium, two basic changes are seen. First, the enzyme responsible for generating the active form of vitamin D is suppressed, resulting in decreased levels of bioactive vitamin D. Since vitamin D promotes intestinal phosphate absorption, plasma phosphate declines. Second, the transporters responsible for phosphate resorption on renal epithelium are down regulated, resulting in decreased uptake from urine and again a decline in blood phosphorus (17, 18).

1. Itoh, N. and D.M. Ornitz (2004) Trends Genet. 20:563. 
2. Mohammadi, M. et al. (2005) Cytokine Growth Factor Rev. 16:107.
3. Fukumoto, S. (2007) Endocr. J. Sep 14; [Epub ahead of print].
4. Huang, X. et al. (2006) Mol. Carcinog. 45:934. 
5. Goetz, R. et al. (2007) Mol. Cell. Biol. 27:3417.
6. Harmer, N.J. et al. (2004) Biochemistry 43:629.
7. Yamashita, T. et al. (2000) Biochem. Biophys. Res. Commun. 277:494.
8. Shimada, T. et al. (2001) Proc. Natl. Acad. Sci. USA 98:6500.
9. Kato, K. et al. (2006) J. Biol. Chem. 281:18370.
10. Zhang, X. et al. (2006) J. Biol. Chem. 281:15694.
11. Urakawa, I. et al. (2006) Nature 444:770.
12. Hurosu, H. et al. (2006) J. Biol. Chem. 281:6120.
13. Wu, X. et al. (2007) J. Biol. Chem. 282:29069.
14. Moore, D.D. (2007) Science 316:1436.
15. Ogawa, Y. et al. (2007) Proc. Natl. Acad. Sci. USA 104:7432.
16. Kurosu, H. et al. (2007) J. Biol. Chem. 282:26687.
17. Razzaque, M.S. and B. Lanske (2007) J. Endocrinol. 194:1.
18. Liu, S. et al. (2007) Curr. Opin. Nephrol. Hypertens. 16:329.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for FGF-23 Antibody (MAB26291)(7)

Publications using MAB26291

• H Sugiura, A Matsushita, M Futaya, A Teraoka, KI Akiyama, N Usui, N Nagano, K Nitta, K Tsuchiya Fibroblast growth factor 23 is upregulated in the kidney in a chronic kidney disease rat model PLoS ONE, 2018;13(3):e0191706. 2018 [PMID: 29518087] (Western Blot, Rat)
• A Sakurai, T Hasegawa, A Kudo, Z Shen, T Nagai, M Abe, T Yoshida, H Hongo, T Yamamoto, T Yamamoto, K Oda, PHL Freitas, M Li, H Sano, N Amizuka Chronological immunolocalization of sclerostin and FGF23 in the mouse metaphyseal trabecular and cortical bone Biomed. Res., 2017;38(4):257-267. 2017 [PMID: 28794403] (IHC-P, Mouse)
• N Kamiya, R Yamaguchi, O Aruwajoye, A Kim, G Kuroyanagi, M Phipps, NS Adapala, JQ Feng, HKW Kim Targeted disruption of NF1 in osteocyte increases FGF23 and osteoid with osteomalacia-like bone phenotype J. Bone Miner. Res., 2017;0(0):. 2017 [PMID: 28425622] (IHC-P, Mouse)
• I-Ping Chen Dietary phosphate supplement does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia J Negat Results Biomed, 2016;15(1):18. 2016 [PMID: 27784318] (IHC, Mouse)
• Z Liu, T Yamamoto, T Hasegawa, H Hongo, K Tsuboi, E Tsuchiya, M Haraguchi, M Abe, PH Freitas, A Kudo, K Oda, M Li, N Amizuka Immunolocalization of osteocyte-derived molecules during bone fracture healing of mouse ribs Biomed Res, 2016;37(2):141-51. 2016 [PMID: 27108883] (IHC-P, Mouse)
• Spichtig D, Zhang H, Mohebbi N, Pavik I, Petzold K, Stange G, Saleh L, Edenhofer I, Segerer S, Biber J, Jaeger P, Serra A, Wagner C Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. Kidney Int, 2014;85(6):1340-50. 2014 [PMID: 24402093] (IHC-Fr, Rat)
• Gore MO, Welch BJ, Geng W, Kabbani W, Maalouf NM, Zerwekh JE, Moe OW, Sakhaee K Renal phosphate wasting due to tumor-induced osteomalacia: a frequently delayed diagnosis. Kidney Int., 2008;0(0):. 2008 [PMID: 18668025] (ICC, Human)

Bioinformatics

• Gene Symbol: Fgf23
• Uniprot:
  • Q9EPC2()